Business Description
Treace Medical Concepts Inc
NAICS : 339112
SIC : 3845
ISIN : US89455T1097
Total Employee Number:
450Description
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The company operates and manages its business as a single segment: designing, manufacturing, and marketing medical devices for surgeons, ambulatory surgery centers, and hospitals related to the surgical management of bunion and related midfoot deformities.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.72 | |||||
Equity-to-Asset | 0.42 | |||||
Debt-to-Equity | 0.93 | |||||
Debt-to-EBITDA | -1.54 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 0.22 | |||||
Beneish M-Score | -3.66 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 9.4 | |||||
3-Year EBITDA Growth Rate | -1.3 | |||||
3-Year EPS without NRI Growth Rate | -8.7 | |||||
3-Year FCF Growth Rate | 17.3 | |||||
3-Year Book Growth Rate | 7.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 8.07 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 4.13 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 52.13 | |||||
9-Day RSI | 55.65 | |||||
14-Day RSI | 58.6 | |||||
3-1 Month Momentum % | 155.32 | |||||
6-1 Month Momentum % | 46.94 | |||||
12-1 Month Momentum % | -40.2 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.58 | |||||
Quick Ratio | 2.53 | |||||
Cash Ratio | 1.5 | |||||
Days Inventory | 337.05 | |||||
Days Sales Outstanding | 58.77 | |||||
Days Payable | 120.73 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.7 | |||||
Shareholder Yield % | -0.45 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 79.72 | |||||
Operating Margin % | -26.89 | |||||
Net Margin % | -29.44 | |||||
EBITDA Margin % | -22.38 | |||||
FCF Margin % | -12.52 | |||||
OCF Margin % | -6.24 | |||||
ROE % | -66.83 | |||||
ROA % | -31.03 | |||||
ROIC % | -51.09 | |||||
3-Year ROIIC % | -29.8 | |||||
ROC (Joel Greenblatt) % | -67.99 | |||||
ROCE % | -34.56 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 1.32 | |||||
PB Ratio | 3.54 | |||||
Price-to-Tangible-Book | 4.73 | |||||
EV-to-EBIT | -5.28 | |||||
EV-to-EBITDA | -6.31 | |||||
EV-to-Forward-EBITDA | 22.71 | |||||
EV-to-Revenue | 1.41 | |||||
EV-to-Forward-Revenue | 0.53 | |||||
EV-to-FCF | -11.28 | |||||
Price-to-GF-Value | 0.61 | |||||
| Price-to-Net-Current-Asset-Value | 16.19 | |||||
Earnings Yield (Greenblatt) % | -18.94 | |||||
FCF Yield % | -9.51 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TMCI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Treace Medical Concepts Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 207.318 | ||
| EPS (TTM) ($) | -0.97 | ||
| Beta | 3.3111 | ||
| 3-Year Sharpe Ratio | -0.23 | ||
| 3-Year Sortino Ratio | -0.4 | ||
| Volatility % | 130.32 | ||
| 14-Day RSI | 58.6 | ||
| 14-Day ATR ($) | 0.385043 | ||
| 20-Day SMA ($) | 4.01575 | ||
| 12-1 Month Momentum % | -40.2 | ||
| 52-Week Range ($) | 1.17 - 7.78 | ||
| Shares Outstanding (Mil) | 64.87 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Treace Medical Concepts Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Treace Medical Concepts Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 16:30 | In 128 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 127 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 16:30 | In 37 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 36 days | ||
| Sidoti Small Cap Conference | 2026-06-18 13:45 | 4.01 (-1.72%) | ||
| General meeting for 2026 | 2026-05-19 11:00 | 2.75 (+4.17%) | ||
| First quarter earnings conference call for 2026 | 2026-05-08 08:00 | 1.92 (+0.52%) | ||
| First quarter earnings results for 2026 | 2026-05-08 | 1.92 (+0.52%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-27 08:00 | 2.10 (+2.44%) | ||
| Annual report for 2025 | 2026-02-27 | 2.10 (+2.44%) |
Show
Entries
Treace Medical Concepts Inc Frequently Asked Questions
What is Treace Medical Concepts Inc(TMCI)'s stock price today?
The current price of TMCI is $4.21. The 52 week high of TMCI is $7.78 and 52 week low is $1.17.
When is next earnings date of Treace Medical Concepts Inc(TMCI)?
The next earnings date of Treace Medical Concepts Inc(TMCI) is 2026-08-07 Est..
Does Treace Medical Concepts Inc(TMCI) pay dividends? If so, how much?
Treace Medical Concepts Inc(TMCI) does not pay dividend.
Guru Commentaries on NAS:TMCI
No articles.
Press Release
Articles on Treace Medical Concepts Inc
No articles.